Prevalence and impact of vaginal symptoms among postmenopausal women.
about
Menopausal Symptoms and Their ManagementClinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophyVaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe drynessOspemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trialManagement of Vaginal Atrophy: Implications from the REVIVE Survey.A systems biology approach investigating the effect of probiotics on the vaginal microbiome and host responses in a double blind, placebo-controlled clinical trial of post-menopausal womenSafety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopausePrevalence, incidence, and treatments of Dupuytren's disease in the United States: results from a population-based studyClinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.A Population-Based Study of Peyronie's Disease: Prevalence and Treatment Patterns in the United StatesUpdate on alternative therapies for vulvovaginal atrophyVaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause.Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors.Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopauseMacro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a post hoc analysis of REVIVE survey data.Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophyFractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women.Barriers to effective treatment of vaginal atrophy with local estrogen therapy.Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy.Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule.Perimenopause: From Research to Practice.Vaginal estrogen for genitourinary syndrome of menopause: a systematic review.Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy.Interest in over-the-counter access to oral contraceptives among women in the United StatesOspemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countriesDiagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group.Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women.Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study.Reviewing the options for local estrogen treatment of vaginal atrophy.Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therapy.Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.Profile of ospemifene in the breast.Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
P2860
Q26796482-1F86FDAC-917D-491D-9BC1-F5C92237B318Q28066699-2E8F8168-E659-4980-B412-105F728A8BA8Q28743240-0F161625-F0C4-4C07-8DBC-A4268553E04CQ30277966-E7968AD4-00FD-431C-B36D-F5143ED6A45EQ30491432-CE8122C6-C9DC-4780-93C8-36FB9D39C93CQ33809618-42003FBE-BBD7-4176-B271-403543937CDFQ34050627-0C92BB3A-E464-4EA3-AFA7-C3D18C6563EEQ34532021-F0E37DC1-AAE2-4B74-B690-9A492441FE2CQ34975787-F172B049-DFC3-49F7-8C2D-F4C836439B5BQ35009269-02C7DCAE-6AF8-4418-B155-EA5671D65714Q35317535-FC6519BA-A101-4455-913A-2D0A318280BBQ35450218-0C56EB04-50B6-41BF-A1AD-34EA2C32E4BDQ35555617-5CB5B739-2CEA-4403-AA12-051E3AF423A8Q35647630-962A6D38-A6ED-44CC-A916-2C583B2FF7CEQ35824414-C4FD59E0-7ACD-4E12-97A7-FC4B2E856CDFQ36015161-CE728EA5-10C1-461B-B312-1A61E240E6A1Q36108656-8BC615AB-3C54-476C-997D-862D8C8A0944Q36301955-B9D9B460-3D21-4A09-B056-85BE654717D0Q36326412-EDB7C8C6-29DD-4FA9-84F7-493C6FB3DF1DQ36371627-81F96E3A-DB10-4A4B-ABD9-EE965F8F928FQ36702052-66A2287D-B24F-4904-B73E-75C4398EF658Q36706621-CF6AE3C1-8C7F-444A-BB46-BDF88C772EF7Q36762551-76930113-0343-4426-A134-6972BA3BAE25Q36762596-20859EED-2840-4FB8-9D0E-272ECADB98B2Q36806326-D0769B2A-BEEA-4FB8-BA99-AB1275EEA0EFQ36865142-36E70CB8-DA30-40D2-9711-22093475B7F7Q37074908-4D7625FF-20FB-4EA2-B2E3-770DB8BE8E6AQ37161461-FCBF23AA-75BE-4B45-A591-503055B4DE27Q37221035-B01F75AE-049B-42F1-B444-9FEB0EDD8EC9Q37248714-3ABE6766-1EC9-4AD7-813D-D0C417B96702Q37494813-103EC97D-70F6-4DCB-A0B7-36A56B712993Q37533191-01228526-CC33-4C22-BB5A-4620B5E6425EQ37552246-49143049-111F-4F83-A31A-F75B6CE82EFBQ37644593-6F6D49F9-710E-4471-8790-98B52171598EQ37644620-71008442-39FB-4B7B-BB46-56D76AD0A817Q37677579-E4BC9DAE-6CEE-49EE-BFE5-A4717322FE30Q37722587-AA002577-7DD6-4D9E-8D87-2107DFC0BED1Q38121156-C164EDDB-75CA-4D38-9B0F-4F0965CAF2A8Q38129004-D2513D32-CA5B-4E01-96A5-CC21973A7DF5Q38178431-AFC7243D-8367-4A5C-8F7D-31D86C753E50
P2860
Prevalence and impact of vaginal symptoms among postmenopausal women.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Prevalence and impact of vaginal symptoms among postmenopausal women.
@en
Prevalence and impact of vaginal symptoms among postmenopausal women.
@nl
type
label
Prevalence and impact of vaginal symptoms among postmenopausal women.
@en
Prevalence and impact of vaginal symptoms among postmenopausal women.
@nl
prefLabel
Prevalence and impact of vaginal symptoms among postmenopausal women.
@en
Prevalence and impact of vaginal symptoms among postmenopausal women.
@nl
P1476
Prevalence and impact of vaginal symptoms among postmenopausal women.
@en
P2093
Janne Komi
Nanette Santoro
P304
P356
10.1111/J.1743-6109.2009.01335.X
P577
2009-06-01T00:00:00Z